| Dosage | 5MG, 10MG |
|---|---|
| Quantity | 1 Bottle, 2 Bottles, 3+ Bottles |
Tesamorelin
Tesamorelin
Price range: $59.99 through $99.99
A 44-krilos acid GHRH analog that stimulates pituitary gh secretion, studied for visceral adipose tissue reduction in clinical research. Premium Research Peptide.
Frequently Asked Questions
Common questions about Tesamorlin
-
IGF-1 levels increase within 2-4 weeks. Visible reduction in abdominal fat typically begins around 8-12 weeks, with maximal effects at 26 weeks. Clinical trials show 15-18% visceral fat reduction at 6 months.
-
Effects are not sustained after discontinuation. Clinical studies show visceral fat returns to near baseline levels within 26 weeks of stopping treatment. This makes continuous therapy necessary to maintain benefits.
-
No. Tesamorlin stimulates your body's own growth hormone production while preserving natural pulsatility and feedback mechanisms. This is physiologically superior to exogenous HGH, which disrupts natural patterns and carries higher risk of side effects.
-
Tesamorlin is FDA-approved specifically for HIV-associated lipodystrophy, not general weight loss. It selectively reduces visceral (abdominal) fat while preserving subcutaneous fat and muscle mass. The FDA label explicitly states it is not for weight loss management.
-
Regular monitoring includes: IGF-1 levels (should remain in physiological range), glucose tolerance/HbA1c (especially in diabetics), injection site reactions, and periodic assessment of treatment response via waist circumference or imaging.
-
Research shows promising cognitive benefits. A controlled trial demonstrated significant improvements in executive function (P=0.005) and response inhibition (P=0.009) in both healthy older adults and those with mild cognitive impairment, using just 1mg daily.


Reviews
There are no reviews yet.